{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:00:04Z","timestamp":1794711604778,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is associated with a range of persistent symptoms impacting everyday functioning, known as post-COVID-19 condition or long COVID. We undertook a retrospective matched cohort study using a UK-based primary care database, Clinical Practice Research Datalink Aurum, to determine symptoms that are associated with confirmed SARS-CoV-2 infection beyond 12 weeks in non-hospitalized adults and the risk factors associated with developing persistent symptoms. We selected 486,149 adults with confirmed SARS-CoV-2 infection and 1,944,580 propensity score-matched adults with no recorded evidence of SARS-CoV-2 infection. Outcomes included 115 individual symptoms, as well as long COVID, defined as a composite outcome of 33 symptoms by the World Health Organization clinical case definition. Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs) for the outcomes. A total of 62 symptoms were significantly associated with SARS-CoV-2 infection after 12 weeks. The largest aHRs were for anosmia (aHR 6.49, 95% CI 5.02\u20138.39), hair loss (3.99, 3.63\u20134.39), sneezing (2.77, 1.40\u20135.50), ejaculation difficulty (2.63, 1.61\u20134.28) and reduced libido (2.36, 1.61\u20133.47). Among the cohort of patients infected with SARS-CoV-2, risk factors for long COVID included female sex, belonging to an ethnic minority, socioeconomic deprivation, smoking, obesity and a wide range of comorbidities. The risk of developing long COVID was also found to be increased along a gradient of decreasing age. SARS-CoV-2 infection is associated with a plethora of symptoms that are associated with a range of sociodemographic and clinical risk factors.<\/jats:p>","DOI":"10.1038\/s41591-022-01909-w","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T12:03:23Z","timestamp":1658750603000},"page":"1706-1714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1011,"title":["Symptoms and risk factors for long COVID in non-hospitalized adults"],"prefix":"10.1038","volume":"28","author":[{"given":"Anuradhaa","family":"Subramanian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6816-1279","authenticated-orcid":false,"given":"Krishnarajah","family":"Nirantharakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5656-1198","authenticated-orcid":false,"given":"Sarah","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puja","family":"Myles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna M.","family":"Gokhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Taverner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9561-5141","authenticated-orcid":false,"given":"Joht Singh","family":"Chandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9403-1593","authenticated-orcid":false,"given":"Kirsty","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Simms-Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop D.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Kidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin","family":"Okoth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hotham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7416-7610","authenticated-orcid":false,"given":"Nasir","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Cockburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siang Ing","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace M.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2061-091X","authenticated-orcid":false,"given":"Georgios V.","family":"Gkoutos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9122-8251","authenticated-orcid":false,"given":"Olalekan Lee","family":"Aiyegbusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"McMullan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7849-0087","authenticated-orcid":false,"given":"Alastair K.","family":"Denniston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Sapey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet M.","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2147-5614","authenticated-orcid":false,"given":"David C.","family":"Wraith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Leggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Iles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm J.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Marwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin Haf","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8492-0020","authenticated-orcid":false,"given":"Louise J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Camaradou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1856-837X","authenticated-orcid":false,"given":"Melanie","family":"Calvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0096-1413","authenticated-orcid":false,"given":"Shamil","family":"Haroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"key":"1909_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41584-021-00608-z","volume":"17","author":"M Ramos-Casals","year":"2021","unstructured":"Ramos-Casals, M., Brito-Zer\u00f3n, P. & Mariette, X. Systemic and organ-specific immune-related manifestations of COVID-19. Nat. Rev. Rheumatol. 17, 315\u2013332 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1909_CR2","unstructured":"Office for National Statistics. The prevalence of long COVID symptoms and COVID-19 complications. https:\/\/www.ons.gov.uk\/news\/statementsandletters\/theprevalenceoflongcovidsymptomsandcovid19complications (2020)."},{"key":"1909_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-020-06001-y","volume":"20","author":"E Ladds","year":"2020","unstructured":"Ladds, E. et al. Persistent symptoms after COVID-19: qualitative study of 114 long COVID patients and draft quality principles for services. BMC Health Serv. Res. 20, 1\u201313 (2020).","journal-title":"BMC Health Serv. Res."},{"key":"1909_CR4","unstructured":"NICE. COVID-19 Rapid Guideline: Managing the Long-term Effects of COVID-19. (NICE, 2020)."},{"key":"1909_CR5","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","volume":"27","author":"A Nalbandian","year":"2021","unstructured":"Nalbandian, A. et al. Post-acute COVID-19 syndrome. Nat. Med. 27, 601\u2013615 (2021).","journal-title":"Nat. Med."},{"key":"1909_CR6","unstructured":"WHO. A clinical case definition of post-COVID-19 condition by a Delphi consensus. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (2021)."},{"key":"1909_CR7","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1001\/jama.2020.19719","volume":"324","author":"C Del Rio","year":"2020","unstructured":"Del Rio, C., Collins, L. F. & Malani, P. Long-term health consequences of COVID-19. JAMA 324, 1723\u20131724 (2020).","journal-title":"JAMA"},{"key":"1909_CR8","doi-asserted-by":"publisher","first-page":"101019","DOI":"10.1016\/j.eclinm.2021.101019","volume":"38","author":"HE Davis","year":"2021","unstructured":"Davis, H. E. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. eClinicalMedicine 38, 101019 (2021).","journal-title":"eClinicalMedicine"},{"key":"1909_CR9","doi-asserted-by":"publisher","first-page":"e2128568","DOI":"10.1001\/jamanetworkopen.2021.28568","volume":"4","author":"D Groff","year":"2021","unstructured":"Groff, D. et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw. Open 4, e2128568 (2021).","journal-title":"JAMA Netw. Open"},{"key":"1909_CR10","doi-asserted-by":"publisher","first-page":"e1003773","DOI":"10.1371\/journal.pmed.1003773","volume":"18","author":"M Taquet","year":"2021","unstructured":"Taquet, M. et al. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 18, e1003773 (2021).","journal-title":"PLoS Med."},{"key":"1909_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/01410768211032850","volume":"114","author":"OL Aiyegbusi","year":"2021","unstructured":"Aiyegbusi, O. L. et al. Symptoms, complications and management of long COVID: a review. J. R. Soc. Med. 114, 428\u2013442 (2021).","journal-title":"J. R. Soc. Med."},{"key":"1909_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-95565-8","volume":"11","author":"S Lopez-Leon","year":"2021","unstructured":"Lopez-Leon, S. et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci. Rep. 11, 1\u201312 (2021).","journal-title":"Sci. Rep."},{"key":"1909_CR13","doi-asserted-by":"publisher","first-page":"e005427","DOI":"10.1136\/bmjgh-2021-005427","volume":"6","author":"M Michelen","year":"2021","unstructured":"Michelen, M. et al. Characterising long COVID: a living systematic review. BMJ Glob. Heal. 6, e005427 (2021).","journal-title":"BMJ Glob. Heal."},{"key":"1909_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S0140-6736(20)32656-8","volume":"397","author":"C Huang","year":"2021","unstructured":"Huang, C. et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 397, 220\u2013232 (2021).","journal-title":"Lancet"},{"key":"1909_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41586-021-03553-9","volume":"594","author":"Z Al-Aly","year":"2021","unstructured":"Al-Aly, Z., Xie, Y. & Bowe, B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 594, 259\u2013264 (2021).","journal-title":"Nature"},{"key":"1909_CR16","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41591-021-01292-y","volume":"27","author":"CH Sudre","year":"2021","unstructured":"Sudre, C. H. et al. Attributes and predictors of long COVID. Nat. Med. 27, 626\u2013631 (2021).","journal-title":"Nat. Med."},{"key":"1909_CR17","doi-asserted-by":"publisher","unstructured":"Jacobs, L. G. et al. Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. PLoS ONE https:\/\/doi.org\/10.1371\/journal.pone.0243882 (2020).","DOI":"10.1371\/journal.pone.0243882"},{"key":"1909_CR18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.cmi.2020.09.052","volume":"27","author":"C Carvalho-Schneider","year":"2021","unstructured":"Carvalho-Schneider, C. et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin. Microbiol. Infect. 27, 258\u2013263 (2021).","journal-title":"Clin. Microbiol. Infect."},{"key":"1909_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43168-020-00049-4","volume":"15","author":"I Galal","year":"2021","unstructured":"Galal, I. et al. Determinants of persistent post-COVID-19 symptoms: value of a novel COVID-19 symptom score. Egypt. J. Bronchol. 15, 1\u20138 (2021).","journal-title":"Egypt. J. Bronchol."},{"key":"1909_CR20","doi-asserted-by":"crossref","unstructured":"Hughes, S. E. et al. Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis. BMJ https:\/\/www.bmj.com\/content\/377\/bmj-2022-070230 (2022).","DOI":"10.1136\/bmj-2022-070230"},{"key":"1909_CR21","doi-asserted-by":"publisher","first-page":"e011664","DOI":"10.1136\/bmjopen-2016-011664","volume":"6","author":"SJ Price","year":"2016","unstructured":"Price, S. J. et al. Is omission of free text records a possible source of data loss and bias in clinical practice research datalink studies? A case\u2013control study. BMJ Open 6, e011664 (2016).","journal-title":"BMJ Open"},{"key":"1909_CR22","doi-asserted-by":"publisher","unstructured":"Wood, A. et al. Linked electronic health records for research on a nationwide cohort of more than 54 million people in England: data resource on behalf of the CVD-COVID-UK consortium. BMJ https:\/\/doi.org\/10.1136\/bmj.n826 (2021).","DOI":"10.1136\/bmj.n826"},{"key":"1909_CR23","unstructured":"NHS. 6. Results and Findings. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/coronavirus-as-recorded-in-primary-care\/march-2020-21\/results-and-findings (2021)."},{"key":"1909_CR24","unstructured":"Office for National Statistics. Prevalence of Ongoing Symptoms Following Coronavirus (COVID-19) Infection in the UK. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/bulletins\/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk\/4june2021 (2021)."},{"key":"1909_CR25","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/s41591-021-01433-3","volume":"27","author":"B Blomberg","year":"2021","unstructured":"Blomberg, B. et al. Long COVID in a prospective cohort of home-isolated patients. Nat. Med. 27, 1607\u20131613 (2021).","journal-title":"Nat. Med."},{"key":"1909_CR26","unstructured":"Office for National Statistics. Prevalence of Ongoing Symptoms Following Coronavirus (COVID-19) Infection in the UK. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/bulletins\/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk\/7april2022 (2022)."},{"key":"1909_CR27","doi-asserted-by":"publisher","first-page":"e065834","DOI":"10.1136\/bmj-2021-065834","volume":"375","author":"HR Whittaker","year":"2021","unstructured":"Whittaker, H. R. et al. GP consultation rates for sequelae after acute COVID-19 in patients managed in the community or hospital in the UK: population-based study. Brit. Med. J. 375, e065834 (2021).","journal-title":"Brit. Med. J."},{"key":"1909_CR28","doi-asserted-by":"publisher","first-page":"e060413","DOI":"10.1136\/bmjopen-2021-060413","volume":"12","author":"S Haroon","year":"2022","unstructured":"Haroon, S. et al. Therapies for long COVID in non-hospitalised individuals: from symptoms, patient-reported outcomes and immunology to targeted therapies (the TLC study). BMJ Open 12, e060413 (2022).","journal-title":"BMJ Open"},{"key":"1909_CR29","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1093\/ije\/dyz034","volume":"48","author":"A Wolf","year":"2019","unstructured":"Wolf, A. et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int. J. Epidemiol. 48, 1740 (2019).","journal-title":"Int. J. Epidemiol."},{"key":"1909_CR30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10654-020-00677-6","volume":"36","author":"KM Gokhale","year":"2021","unstructured":"Gokhale, K. M. et al. Data extraction for epidemiological research (DExtER): a novel tool for automated clinical epidemiology studies. Eur. J. Epidemiol. 36, 165\u2013178 (2021).","journal-title":"Eur. J. Epidemiol."},{"key":"1909_CR31","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jama.2020.9151","volume":"325","author":"K Yadav","year":"2021","unstructured":"Yadav, K. & Lewis, R. J. Immortal time bias in observational studies. JAMA 325, 686\u2013687 (2021).","journal-title":"JAMA"},{"key":"1909_CR32","doi-asserted-by":"publisher","unstructured":"Hughes, S. E. et al. Development and validation of the symptom burden questionnaire for long COVID (SBQ-LC): Rasch analysis. BMJ https:\/\/doi.org\/10.1136\/bmj-2022-070230 (2022).","DOI":"10.1136\/bmj-2022-070230"},{"key":"1909_CR33","doi-asserted-by":"publisher","unstructured":"Nylund, K. L., Asparouhov, T. & Muth\u00e9n, B. O. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Struct. Equ. Modeling https:\/\/doi.org\/10.1080\/10705510701575396 (2007).","DOI":"10.1080\/10705510701575396"},{"key":"1909_CR34","doi-asserted-by":"publisher","unstructured":"Weller, B. E., Bowen, N. K. & Faubert, S. J. Latent class analysis: a guide to best practice. J. Black Psychol. https:\/\/doi.org\/10.1177\/0095798420930932 (2020).","DOI":"10.1177\/0095798420930932"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01909-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01909-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01909-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T02:08:36Z","timestamp":1660874916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01909-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1909"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-01909-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1343889\/v1","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]},"assertion":[{"value":"9 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.C. is Director of the Birmingham Health Partners Center for Regulatory Science and Innovation and Director of the Center for Patient-Reported Outcomes Research and is an NIHR Senior Investigator. M.C. receives funding from the NIHR Birmingham Biomedical Research Center (BRC), NIHR Surgical Reconstruction and Microbiology Research Center (SRMRC), NIHR Birmingham-Oxford Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics and NIHR Applied Research Collaboration (ARC) West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, SPINE UK, UKRI, UCB Pharma, Janssen, GSK and Gilead. M.C. has received personal fees from Astellas, Aparito, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute outside the submitted work. S.E.H. receives funding from NIHR ARC, West Midlands and the NIHR BTRU in Precision Transplant and Cellular Therapeutics at the University of Birmingham. S.E.H. declares personal fees from Cochlear and Aparito outside the submitted work. O.L.A. receives funding from the NIHR Birmingham BRC, NIHR ARC, West Midlands, NIHR BTRU in Precision Transplant and Cellular Therapeutics at the University of Birmingham and University Hospitals Birmingham NHS Foundation, Innovate UK, Gilead Sciences, Janssen Pharmaceuticals and Sarcoma UK. O.L.A. declares personal fees from Gilead Sciences, GSK and Merck outside the submitted work. C.M. receives funding from NIHR SRMRC, NIHR BTRU in Precision Transplant and Cellular Therapeutics and Innovate UK and has received personal fees from Aparito outside the submitted work. A.D.S. is supported by a postdoctoral fellowship from THIS Institute, NIHR University College London Hospitals BRC, grants from NIHR and British Heart Foundation Accelerator Award. E.S. has received grants from the Wellcome Trust, MRC, NIHR EME, NIHR HTA, HDR-UK, BLF, EPSRC and Alpha 1 Foundation in the last 36 months. She has been an honorarium for lectures about COVID-19 treatments, which are run by GSK, attended a virtual conference at the European Respiratory Society in 2020 that was funded by AstraZeneca and participated in an advisory board for COPD, which is run by Boehringer Ingelheim. S.M. has received funding from NIHR (RfPB, PGfAR, HTA and EME streams), UKRI, ESRC and the Midlands Engine. He has attended educational events funded by Psychiatric Genetic Testing, Janssen and Lundbeck in the last 5 years. P.M., T.W., C.I. and E.L. are employees of CPRD, the data custodians for CPRD Aurum. CPRD is jointly sponsored by the UK Government\u2019s MHRA and NIHR. As a not-for-profit UK Government body, CPRD seeks to recoup the cost of delivering its research services to academic, industry and government researchers through research user license fees. J.C. receives funding from NIHR on PPI from a study at UCL (NIHR132914) and a study at University Hospitals Bristol (NIHR203304). J.C. is a lay member on the NICE COVID expert panel and a citizen partner on the COVID END Evidence Synthesis Global Horizon Scanning panel. J.C. declares personal fees from MEDABLE, GlaxoSmithKline and Roche Canada outside of submitted work. K.L.M. is a trustee and volunteer at long COVID SOS. K.L.M. is on the long COVID Advisory Board for Dysautonomia International and is employed by NIHR. T.M. receives funding from NIHR ARC, West Midlands. G.V.G. receives funding from the NIHR Birmingham ECMC, NIHR Birmingham SRMRC, Nanocommons H2020-EU (731032), MAESTRIA (grant agreement no. 965286) and the MRC Health Data Research UK (HDRUK\/CFC\/01). J.M.L. receives funding from the MRC, Versus Arthritis, NIHR, FOREUM, UKSPINE and the Scar Free Foundation and declares personal fees from Bayer. F.K. is supported by an NIHR Doctoral Fellowship award (grant no. 300688). M.J.P. is supported by NIHR BRC. All other co-authors declare no competing interests. The views expressed are those of the investigators, and the funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}